Bioxytran reports functional gains in first CIDP patient treated with PLICID galectin antagonist

Reuters2026/08/11 11:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Bioxytran reported clinical observations from the first CIDP patient treated with investigational PLICID, a once-weekly intravenous galectin antagonist.
Results have already been presented, showing reported improvement in finger function and walking ability.
No adverse events were reported during the treatment course.
The update was based on a single patient, limiting conclusions on safety or efficacy.
Bioxytran plans a larger, appropriately designed clinical study to further evaluate PLICID in CIDP.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioxytran Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608110700PRIMZONEFULLFEED9807561) on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Bioxytran reports functional gains in first CIDP patient treated with PLICID galectin antagonist

You may also like

Crypto prices